AllSquare Wealth Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$18.3K Hold
660
0.01% 331
2025
Q2
$16.1K Hold
660
0.01% 340
2025
Q1
$13.7K Hold
660
0.01% 351
2024
Q4
$15.5K Hold
660
0.01% 331
2024
Q3
$16.9K Hold
660
0.01% 330
2024
Q2
$15.5K Hold
660
0.01% 330
2024
Q1
$19K Hold
660
0.01% 308
2023
Q4
$21.7K Hold
660
0.01% 286
2023
Q3
$18.4K Hold
660
0.01% 304
2023
Q2
$20.9K Hold
660
0.01% 294
2023
Q1
$19.8K Hold
660
0.01% 304
2022
Q4
$18.6K Hold
660
0.01% 298
2022
Q3
$22K Hold
660
0.02% 271
2022
Q2
$21K Hold
660
0.01% 282
2022
Q1
$30K Hold
660
0.02% 270
2021
Q4
$40K Hold
660
0.02% 246
2021
Q3
$49K Hold
660
0.03% 224
2021
Q2
$61K Sell
660
-100
-13% -$8.5K 0.04% 205
2021
Q1
$67K Buy
+760
New +$75.4K 0.04% 187

Other funds holding ARKG

AllSquare Wealth Management's ARKG Position: Q3 2025 in Review

AllSquare Wealth Management held its ARK Genomic Revolution ETF (ARKG) position steady in Q3 2025 at 660 shares worth $18.3K. The position accounts for 0.01% of the portfolio, ranked #331.

AllSquare Wealth Management first reported a position in ARKG in Q1 2021 and has held it in 19 quarters since. The position peaked at $67K in Q1 2021. 231 funds tracked by Wall St. Rank hold ARKG as of Q3 2025.

  • AllSquare Wealth Management held 660 shares of ARK Genomic Revolution ETF worth $18.3K as of Q3 2025.
  • AllSquare Wealth Management left its ARK Genomic Revolution ETF share count unchanged in Q3 2025.
  • ARK Genomic Revolution ETF made up 0.01% of AllSquare Wealth Management's portfolio in Q3 2025, its #331 holding.
  • AllSquare Wealth Management first reported a position in ARK Genomic Revolution ETF in Q1 2021 and has held it in 19 quarters since.
  • AllSquare Wealth Management's ARK Genomic Revolution ETF position peaked at $67K in Q1 2021.
  • 231 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2025.

Based on AllSquare Wealth Management's 13F filing for Q3 2025, filed 12 Jan 2026.